We studied the therapeutic efficacy of an intravenously injected antifibrotic agent encapsulated in liposomes on inhibiting collagen accumulation in hypertensive blood vessels. cis-4-Hydroxy-L-proline (cHyp) in liposomes was injected into rats exposed to 10% 02, and drug effect was evaluated by measuring right ventricular pressure and hydroxyproline content of the pulmonary artery. Right ventricular pressure was 11±1 mm Hg (mean+SEM) 5 days after a single intravenous injection of 200 mg/kg cHyp in liposomes compared with 14+1 mm Hg in rats injected with empty liposomes; hydroxyproline content was also reduced by cHyp treatment (87±6 versus 107±7 pg per vessel) (p<0.05 for both, n=6-9). Injections of cHyp in liposomes every 5 days partially prevented hypertension and vascular collagen accumulation during a 3-week exposure to hypoxia, and the dose required was one tenth the dose of unencapsulated cHyp. Therapeutic doses of cHyp in liposomes injected for 6 months affected tensile properties of main pulmonary artery and aorta, but there were no apparent histological effects on other organs. Liposomes injected intravenously were identified in pulmonary artery endothelial cells. The prolonged effect of a single injection of cHyp in liposomes may be due to uptake of the liposomes by the endothelium. Liposome delivery of drugs to the arterial wall may be useful in the study and treatment of hypertensive vascular disease. (Circulation Research 1992;70:912-922) KEY WoRDs * drug delivery * hypertension * fibrosis * blood vessel * proline analogue T he therapeutic efficacy of drugs has been enhanced by complexing them with a variety of carrier vehicles.1 One vehicle that has been used extensively is liposomes or lipid bilayers that enclose an aqueous compartment.23 When drug-laden liposomes are injected intravenously, the drug is not diluted or degraded in the circulation and reaches tissues in concentrated form.23 However, penetration of liposomes through blood vessel walls of nonreticuloendothelial organs is restricted.4 Although liposomes for the most part are unable to leave the circulation, free drug released from liposomes diffuses through capillary walls to reach nearby cells.23 We reasoned that confinement of liposomes to the vascular compartment may be an advantage in enhancing drug delivery to blood vessels to treat vascular disorders.
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To test this concept, we studied the efficacy of an antifibrotic agent injected intravenously in liposomes by evaluating its ability to interfere with collagen accumulation in hypertensive vascular remodeling in the rat. The agent, cis-4-hydroxy-L-proline (cHyp), is a proline analogue that attenuates hypoxic pulmonary hypertension by blocking vascular collagen accumulation.5 '6 We postulated that liposomes containing cHyp are taken up from the blood by endothelial cells, and cHyp is slowly released from the liposomes into the vicinity of collagen-producing cells in the walls of pulmonary arteries undergoing structural remodeling. When tested in a rat model of hypoxic pulmonary hypertension, liposomes were taken up by the endothelium, and treatment with liposome delivery was substantially more effective than unencapsulated cHyp. Our results suggest that liposome delivery of drugs to the arterial wall may be useful in the study and treatment of hypertensive vascular diseases. In addition, targeting proline analogues in liposomes to vascular tissues undergoing fibrosis may be a feasible approach to long-term suppression of local collagen accumulation.
Materials and Methods Materials
Outbred 6-week-old male Sprague-Dawley rats (Crl: CD[SD]BR) weighing 193-203 g were used (Charles River Breeding Laboratories, Wilmington, Mass.). Materials were L-a-dipalmitoylphosphatidylcholine (780 g/mol) (Avanti Polar Lipids, Birmingham, Ala.); penicillin, streptomycin, gentamicin, cholesterol (386.6 g/mol), stearylamine (269.5 g/mol), and ferritin (type I from horse spleen) (Sigma Chemical Co., St. Louis, Mo.); cHyp, rabbit anti-factor VIII antibody and fluorescein isothiocyanate-goat anti-rabbit antibody (Calbiochem Corp., La Jolla, Calif.); 1,1',dioctadecyl-3,3,3',3'-tetramethylindocarbocyanineperchlorate (diI) (Molecular Probes, Inc., Eugene, Ore.); ['4C]-L-proline (260 mCi/ mM), methanol and quaternary ammonium hydroxide (Protosol) (New England Nuclear Co., Boston, Mass.); [3H]benzoyl-Phe-Ala-Pro (20 Ci/mM) (Peninsula Laboratories, Belmont, Calif.); fluorescent latex microspheres (Fluoresbrite, Polysciences, Inc., Warrington, Pa.); medium 199 (Flow Laboratories, McLean, Va.); and fetal bovine serum (HyClone Laboratories, Logan, Utah). Liquid scintillation fluids were Econofluor (New England Nuclear) and Liquescent (National Diagnostics, Inc., Somerville, N.J.). Chemicals were analytical grade.
Animals
Animals were kept for 1 week before study and were fed water and food ad libitum. Rats were exposed to hypoxia (10% 02-90% N2), and mean right ventricular pressure (RVP) (measured in animals anesthetized with 50 mg/kg i.p. pentobarbital sodium while breathing air), hematocrit, and the ratio of weights of the cardiac ventricles (RV/[LV+S]) were measured as previously described.7 Air-breathing animals were age and weight matched to hypoxic animals.7
Biochemistry
Whole segments of blood vessels were hydrolyzed,5 and total hydroxyproline and protein contents were measured in triplicate using a calorimetric method for hydroxyproline8 and the ninhydrin method9 with leucine as standard for protein. Results were expressed as content per vessel.
Liposomes
Unilamellar, positively charged, small phospholipid vesicles (liposomes) were prepared by reversed-phase evaporation by the method of Szoka and Papahadjopou-los10 as modified by Turrens and associates."1 The following materials were added to the lipid mixture: cHyp (1.25 g), diI (10 ,ul of 3.7 ,uM diI solution),
[14C]-L-proline (10 , uCi) , ferritin (0.5 mg), and phosphate-buffered saline ("empty" liposomes). Lipid phosphorus was measured using the ammonium molybdate method of Chen and associates12 as modified by Ames and Dubin.13 Liposome diameter was estimated by a fluorescence-activated cell sorter using fluorescent latex microspheres as size markers. The diameter of 90% of the liposomes ranged from 100 to 220 nm. Entrapment was estimated as the percentage of ['4C]-L-proline sequestered in liposomes and was found to be 51±6% (n = 11). Structural integrity of liposomes, assessed by retention of [14C]-L-proline, remained constant during storage at 4°C for 21 days.
Injections
Free cHyp (cHyp dissolved in saline) or saline was injected subcutaneously in a volume of -0.5 ml. For intravenous injections, rats were anesthetized (25 mg/kg i.p. thiopental sodium), and liposomes or saline was injected (-18 ,Lmol phospholipid, -0.5 ml) via the needle. Injections were administered within 20 minutes before exposure to hypoxia or during hypoxia.
Experimental Design
Five treatment protocols were designed to study the efficacy and duration of effect of cHyp in liposomes and free cHyp. Additional experiments were done to evaluate the effect of an acute injection of liposomes on pulmonary blood pressure, chronic administration of cHyp, organ distribution and retention of radiolabeled liposomes, uptake of liposomes by pulmonary artery endothelial cell monolayers, and in vivo localization of liposomes in pulmonary arterioles.
The effect of cHyp on preventing hypoxic pulmonary hypertension was evaluated using five parameters of exposure to hypoxia: RVP, RV/(LV+ S), hematocrit, and hydroxyproline and protein contents of the main pulmonary artery.7 Animals were exposed to hypoxia or air and were studied at 0 (before exposure) and 3, 5, 7, or 21 days. At each time, the five parameters were compared among four groups: hypoxic treated with cHyp, air treated with cHyp, hypoxic treated with a control substance, and air treated with a control substance. The cHyp was administered as free cHyp or as cHyp in liposomes. The control substance for cHyp was saline and for cHyp in liposomes was empty liposomes. Efficacy of free cHyp and cHyp in liposomes was determined as the minimal total dose of cHyp administered during exposure to hypoxia that prevented collagen accumulation and pulmonary hypertension.
Treatment Protocols
Protocol 1: Free versus cHyp in liposomes at 3 days. To assess whether a single injection of cHyp in liposomes was more effective than free cHyp injected subcutaneously or intravenously, animals were given free cHyp (200 mg/kg s.c. twice daily for 3 days, 100 mg/kg s.c. twice daily for 3 days, or 200 mg/kg i.v. once before hypoxia) (groups 1-3, respectively) or single doses of 100 mg/kg (group 4) or 200 mg/kg (group 5) cHyp in liposomes and were evaluated at 3 days of exposure to hypoxia.
Protocol 2: Duration of effect of a single dose of cHyp entrapped in liposomes. To determine the duration of effect of a single intravenous dose of 200 mg/kg cHyp in liposomes, animals were studied at 5 days (group 6) and 7 days (group 7) of hypoxia. Protocol 3: Single dose of cHyp entrapped in liposomes after reticuloendothelial blockade. To determine whether reticuloendothelial (RE) blockade before injection of cHyp in liposomes results in enhanced uptake in lung tissue, a single dose of empty liposomes (--18 ,mol phospholipid, -0.5 ml) was injected intravenously 30 minutes before a single intravenous dose of 50 mg/kg (group 8) or 100 mg/kg (group 9) of cHyp in liposomes. Effects were evaluated at 3 days of exposure to hypoxia.
Protocol 4: Duration of effect of a single dose of cHyp entrapped in liposomes after RE blockade. To determine whether RE blockade results in a longer duration of effect, a single intravenous dose (100 mg/kg) of cHyp in liposomes was injected, and animals were evaluated at 5 days (group 10) and 7 days (group 11).
Protocol 5: Intermittent doses of cHyp entrapped in dorsal vein of the penis over 5 seconds with a 30-gauge liposomes. To determine whether intermittent single doses (200 mg/kg) of cHyp in liposomes injected intravenously before and every 5 days during exposure to hypoxia were effective, animals were studied at 21 days of exposure to hypoxia (group 12). These results were compared with twice daily subcutaneous injections of free cHyp from a previous study.5
Effect ofAcute Injection of Liposomes on Pulmonary Blood Pressure Anesthetized, catheterized, air-breathing rats were injected with a bolus of liposomes to determine the acute pressor effect of liposomes. After RVP was stable for 5-10 minutes, a bolus of empty liposomes (-18 ,umol phospholipid, -1.0 ml) or saline (-1.0 ml) was injected via the dorsal vein of the penis, and RVP was recorded continually until it returned to baseline. The maximal increase in RVP during the first 2 minutes after injection was compared with mean RVP before injection.
Chronic Administration
Effects of long-term injections were evaluated in four groups of air-breathing rats injected with saline, -0.5 ml s.c. twice daily; empty liposomes, -0.5 ml i.v. every 5 days; cHyp, 200 mg/kg s.c. twice daily; and cHyp in liposomes, 200 mg/kg i.v. every 5 days. Indexes of drug effect were body weight, hematocrit, chemical constituents of blood, histopathology of visceral organs, static mechanical properties of blood vessels, and hydroxyproline content of blood vessels. For the latter two measurements, segments of standard length (2-3 mm) were excised from the main pulmonary artery, the left extrapulmonary branch, the intrapulmonary axial artery of the left lung, and the lower third of the thoracic aorta. Linear dimensions were measured in four separate regions with a calibrated reticule attached to a light microscope (Laborlux Pol 12, Leica, Inc., Rockleigh, N.J.), and average cross-sectional area was computed. Each segment was mounted on two stainless-steel wires covered with polyethylene PE-50 tubing and suspended in a bath filled with Krebs' solution maintained at 25°C. Mechanical testing of the segments in uniaxial tension was performed using a tensiometer (model 1122, Instron Corp., Canton, Mass.). The specimen was clamped to a moving rigid frame (crosshead) that was lowered at a constant rate, stretching the specimen. The upper end of the specimen was attached to a load cell (50 g) that determined the resultant force. After equilibration for 5 minutes with no stress, a load was applied at a rate of elongation of 5 mm/min; strain rate per minute varied with cross-sectional area. Single-cycle-to-failure tensile testing was performed from which the following material properties were obtained: ultimate tensile stress (crut) or tensile load at failure/area, strain to failure (Em) or percent elongation from an unloaded length to length at failure, and elastic modulus or the slope of the stress-strain curve.14 The elastic moduli of the more horizontal portion of the stress-strain curve (EhON) and the vertical portion (Ever) were measured to evaluate involvement of extension of elastic fibers (Ehor) and collagenous fibers (Ever)."5 A best-fit line was drawn tangent to the linear portions of the horizontal and vertical portions of the stress-strain curves, and slopes of the lines were measured to compute Eho, and Ever. Segments were then removed, and hydroxyproline contents were measured.
Organ Distribution and Retention of Liposomes
Radiolabeled liposomes (-2.2x 10' cpm, 100 ul) were injected intravenously, and uptake in selected organs and blood was measured 6 hours, 5 days, or 7 days later. Tissue samples (-200 mg) were digested in Protosol, an aliquot counted, and results expressed as percent radioactivity injected. Total blood volume was calculated using hematocrit and estimated plasma volume (3.9 ml/100 g body wt).16
Uptake of Liposomes by Pulmonary Artery Endothelial Cell Monolayers
Fresh bovine pulmonary arteries were perfused with sterile phosphate-buffered saline containing 0.1 mg/ml gentamicin, 37°C, until free of blood. The endothelial cells were mechanically removed and placed in medium 199 containing 5% fetal bovine serum, 100 IU/ml penicillin, 100 ,ug/ml streptomycin, and 50 gg/ml gentamicin, pH 7.4, and not fed or moved for 1 week. Thereafter, culture medium was changed twice weekly, and cells were passaged seven times using a 2:1 split. Endothelial cells were identified by phase-contrast microscopy by their characteristic cobblestone appearance in culture,17 the presence of angiotensin converting enzyme activity using ['H]benzoyl-Phe-Ala-Pro as substrate,'8 and factor VIII-related antigen by immunofluorescence.19 Endothelial cells (1 x 105) were added to each 38-mm2 well of a 96-well flat-bottom plate (Microtest II, Falcon Plastics, Oxnard, Calif.) and grown to confluence. Aliquots of liposomes containing ['4C]-L-proline (0.1 ,Ci, -0.2 ,mol phospholipid, -5 gl per well) were added to the monolayers. After incubation for 30 minutes to 5 hours, monolayers were washed, cells were removed, and radioactivity was counted. Uptake of liposomes by cells was estimated as percent total radioactivity.
To determine whether liposomes entered endothelial cells, monolayers were incubated with liposomes labeled with the fluorescent carbocyanine dye diI, a lipid dye with rhodamine-like spectra that is nontoxic.20 Endothelial cells (5 x 10) and 3 ml medium 199 were added to each 175-mm2 well of a six-well flat-bottom plate (Multiwell, Falcon Plastics) and grown to confluence. Aliquots of liposomes labeled with the dye (-0.8 j,mol phospholipid, -20 gl per well) were added to monolayers and incubated for 30 minutes to 5 hours. The monolayers were washed and examined with a microscope (model ICM 405, Carl Zeiss Inc., Thornwood, N.Y.) with an epifluorescence attachment and a standard rhodamine filter at x40 magnification. Endothelial cell monolayers incubated with unlabeled liposomes were used as control.
Localization of Liposomes in Pulmonary Arterioles
Two animals were injected with empty liposomes followed 30 minutes later by a single injection of ferritin-entrapped liposomes. The pulmonary artery was perfused with phosphate-buffered saline until the effluent was clear of blood. The tissue was fixed by perfusion at 100 cm H20 with Karnovsky's fixative. 2 
Results
Effect of Exposure to Hypoxia There were no differences in mean body weights on any day between airand hypoxia-exposed animals treated with the control substance. Rats exposed to hypoxia for 21 days and injected with empty liposomes every 5 days had progressive increases in the five parameters of exposure to hypoxia: RVP increased from 9±1 to 21±2 mm Hg, RV/(LV+S) from 0.24±0.01 to 0.43+0.02, hematocrit from 47±2% to 66+1%, hydroxyproline content from 79±6 to 163±14 ,ug per vessel, and protein content from 1.5±0.1 to 3.2+0.3 mg per vessel (all p<0.05, n=7-8). All parameters were increased as early as 3 days of exposure to hypoxia (Figures 1 and 2 ).
Effect of cHyp on Air-Exposed Animals
Treatment of air-exposed animals with cHyp for 21 / days produced no effects on body weight or any of the five parameters compared with the air-exposed animals treated with the control substance (data not shown).
However, rats injected subcutaneously with free cHyp for 6 months weighed less than rats injected with saline (see below). For a control group, we report only the results of the air-exposed animals treated with the control substance.
Effect of cHyp on Hypoxic Animals
There were no differences in mean body weight on any day between hypoxic animals treated with cHyp and hypoxic animals treated with the control substance.
Treatment Protocols
Protocol 1: Free versus cHyp in liposomes at 3 days. Treatment with 200 mg/kg s.c. free cHyp twice daily for 3 days (group 1) partially prevented the hemodynamic and biochemical changes ( Table 1) . Injection of 100 mg/kg s.c. free cHyp for 3 days (group 2) had no protective effect. A single intravenous dose of 200 mg/kg free cHyp before hypoxia (group 3) and injections of 100 or 200 mg/kg free cHyp twice daily for 3 days in air-breathing rats had no effect. A single dose of 200 mg/kg cHyp entrapped in liposomes injected intravenously before hypoxia (group 5) partially prevented all changes, whereas a dose of 100 mg/kg cHyp entrapped in liposomes (group 4) had no protective effect (Figure 1 ). Protocol 2: Duration of effect of a single dose of cHyp entrapped in liposomes. A single dose of 200 mg/kg cHyp in liposomes injected before exposure to hypoxia suppressed the increases in RVP, RV/(LV+S), and hydroxyproline content for 5 days (group 6), but at day 7 (group 7) the values were at levels of the hypoxic animals treated with empty liposomes (Figure 1 ). The increases in hematocrit and protein content were suppressed for 3 days, but no suppression was present on days 5 and 7. The rates of increase in RVP and hydroxyproline content between days 5 and 7 in the group treated with cHyp in liposomes were similar to those noted between days 0 and 3 in the group treated with empty liposomes. Protocol 3: Single dose of cHyp entrapped in liposomes after RE blockade. In animals with RE blockade, a single dose of 100 mg/kg i.v. cHyp in liposomes partially prevented the increase in RVP and completely prevented the increases in RV/(LV+S) and hydroxyproline content at 3 days (group 9); the increases in hematocrit and protein content at 3 days were not prevented ( Figure 2) . A dose of 50 mg/kg i.v. had no protective effect on any parameter at 3 days (group 8). Thus, a dose of cHyp (100 mg/kg) that was not effective without RE blockade prevented pulmonary hypertension and collagen accumulation in animals with prior RE blockade. (Doses between 50 and 100 mg/kg or > 100 mg/kg were not tested.)
Protocol 4: Duration of effect of a single dose of cHyp entrapped in liposomes after RE blockade. In animals with RE blockade, a single dose of 100 mg/kg cHyp in liposomes injected before exposure to hypoxia suppressed the increases in RVP, RV/(LV+S), and hydroxyproline content for 5 days (group 10), but at day 7 (group 11) the values were at levels of the hypoxic animals treated with empty liposomes (Figure 2 ). The increases in hematocrit and protein content were not suppressed on any day. As noted in protocol 2, there was a 5-day delay in the increases in RVP and hydroxyproline content in the group treated with cHyp in liposomes compared with the group treated with empty liposomes. Importantly, the dose required to suppress these changes in the group with RE blockade (100 mg/kg) was one half of the dose given to the animals without RE blockade (200 mg/kg).
Protocol 5: Intermittent doses of cHyp entrapped in liposomes. Injections of cHyp in liposomes every 5 days during hypoxic exposure (group 12) partially prevented cis-4-hydroxy-L-proline, not contained in liposomes. Animals were exposed to hypoxia (10% 02) or air for 3 days and were treated with cHyp using the doses and regimens indicated. treated with empty liposomes intravenously every 5 days; o, hypoxia exposed treated with 200 mg/kg i.v. cis-hydroxyproline in liposomes every 5 days; A, hypoxia exposed treated with 200 mg/kg s.c. free cis-hydroxyproline twice daily (data from Reference 5); *, air exposed treated with empty liposomes intravenously every 5 days. *pc0.05 compared with air-exposed group; tpc0.05 compared with hypoxia-exposed group treated with empty liposomes. Data points, mean; brackets, +SEM; n=6-9.
increases in RVP, RV/(LV+S), and hydroxyproline content on day 21 (Figure 3 ). This regimen had no effect on hematocrit: 68+1% in the hypoxic group injected with cHyp in liposomes versus 66+1% in the hypoxic group injected with empty liposomes (NS, n=6-9). Protein content was decreased by administration of cHyp: 2.4+0.2 mg in the hypoxic group injected with cHyp in liposomes versus 3.2±0.3 mg in the hypoxic group injected with empty liposomes (p<0.05, n=6-9).
To determine whether the effective dose of intermittent injections of cHyp in liposomes was less than free cHyp, we compared the previously reported results using cHyp 200 mg/kg s.c. twice daily for 21 days5 with those using cHyp 200 mg/kg i.v. in liposomes every 5 days. The regimens were equally effective in preventing pulmonary hypertension and vascular collagen accumulation (Figure 3 ). The total dose of cHyp in liposomes was one tenth that of the free cHyp dose.
Effect ofAcute Injection of Liposomes on Pulmonary Blood Pressure
Mean RVP increased from 9±1 to 11±1 mmHg within 2 minutes after injection of empty liposomes (p<0.05, n=5) and returned to baseline within 4 minutes. Injection of saline under the same conditions had no effect on RVP (9±1 versus 10±1 mm Hg, NS, n=4).
Chronic Administration
No rats died during the 6-month period, and all animals appeared healthy and without petechiae or hemorrhages. No significant differences in body weights were found in groups injected with saline subcutaneously twice daily, empty liposomes intravenously every 5 days, or cHyp in liposomes intravenously every 5 days. Rats injected with free cHyp subcutaneously weighed 11±2% less than rats injected with saline (p<0.05, n=6-9). There were no differences among groups in organ weights, hematocrits, or chemical constituents of blood. Microscopic examination of visceral organs revealed no pathological changes.
Vascular mechanics were obtained only in groups injected intravenously with cHyp in liposomes and empty liposomes. For aorta, our results for the group injected with empty liposomes for oCuS was 2.0±0.3 N/mm2 (n=6) and for Ever was 6.1±1.4 N/mm2 (n=6); these results are in good agreement with those reported by Oxlund and Andreassen27 for o,,,, of 2.1 N/mm2 and for E,er of 6.8 N/mm2. Values for o,uts and Ever in main pulmonary artery and aorta in the group treated with cHyp in liposomes were decreased compared with those of the group treated with empty liposomes (both p<O.05) ( Table 2 ). The values of cr.,s and Ever were not significantly different in extrapulmonary or intrapulmonary arteries of the two groups. Values for Em and Ehor were not different for the two groups in any blood vessel. Hydroxyproline contents among the saline, free cHyp, empty liposomes, and cHyp in liposomes groups in pulmonary arteries or aorta were not significantly different (Table 3) .
Organ Distribution and Retention of Liposomes
After injection of radiolabeled liposomes to airbreathing rats, radioactivity at 6 hours was mostly in the liver, where it reached a value of 48+±4% ( Figure 4A ).
Hepatic radioactivity decreased to values of 3±1% at 5 and 7 days. RE blockade did not decrease uptake in liver. Uptake in spleen was 3±1% at 6 hours and less than 1% at 5 and 7 days; RE blockade increased splenic uptake threefold at 6 hours (p<0.05) ( Figure 4B ). Lungs and kidneys had only minimal amounts of radioactivity. Uptake in lungs was 0.8±0.1% at 6 hours; RE blockade increased uptake to 1.4±0.1% (p<0.05) (Figure 4C) . In kidneys, uptake was 0.7±0.1% at 6 hours; RE blockade increased uptake to 1.2±0.1% (p<0.05) (not shown). At days 5 and 7, uptake in lungs was -0.3% and in kidneys -0.7%. RE blockade produced increased uptake in the lungs and kidneys at 5 days (p<0.05) but not at 7 days. In blood, uptake was 3±1% at 6 hours, 2±1% at 5 days, and 1±1% at 7 days; RE blockade increased the percent uptake in blood at 6 hours but not at 5 and 7 days ( Figure 4D ).
Uptake of Liposomes by Pulmonary Artery Endothelial Cell Monolayers
Uptake of liposomes containing [14C]-L-proline by pulmonary artery endothelial cell monolayers was 3.3±0.3% (n=3) at 30 minutes. Uptake was maximal at 5.4±0.3% (n=3) after 2 hours and remained at that g g Ehor, elastic modulus of horizontal portion of stress-strain curve; Ever, elastic modulus of vertical portion of stress-strain curve; cHyp, cis-4-hydroxy-L-proline; main, main pulmonary artery trunk; extrapulmonary, left extrapulmonary artery; intrapulmonary, axial artery of left lung. Animals exposed to air were injected with empty liposomes or cHyp in liposomes (200 mg/kg) every 5 days for 6 months, and mechanical properties of the blood vessels were measured. *p<0.05 compared with group injected with empty liposomes; analyzed by t test.
level for 5 hours. The t112 for binding of liposomes to pulmonary endothelial cells in culture was -25 minutes. Fluorescence microscopy showed localized distribution of orange-red fluorescence within endothelial cells at 30 minutes to 5 hours, indicating uptake of dil-containing liposomes by endothelial cells (not shown). Fluorescence was at background intensity in monolayers incubated with unlabeled liposomes.
Localization of Liposomes in Pulmonary Arterioles
In tissues not treated with tannic acid, liposomes containing ferritin were visualized in the cytoplasm of endothelial cells of pulmonary arterioles (20-50 ,gm external diameter) but were not clearly distinguished from cellular material (Figures 5A and 5B) . In tissues fixed with 8% tannic acid, however, ferritin-containing liposomes were distinct, although structural details of the cytoplasm were not well preserved ( Figure SC) . Small aggregates of uniformly sized electron-dense ferritin particles surrounded by a lucent "halo" were seen on the plasma membrane and within endothelial cells. The aggregates were located within endosomes, some of which were identified as deep invaginations of the plasmalemma. Less frequently, liposome aggregates and individual liposomes not contained within cytoplasmic vesicles were observed. Liposomes were not clearly identified in basement membrane or in nonendothelial saline, group injected with saline (-0.5 ml s.c. twice daily); cHyp, group injected with 200 mg/kg s.c. cis-4-hydroxy-L-proline twice daily; empty liposomes, group injected intravenously with empty liposomes every 5 days; cHyp in liposomes, group injected with 200 mg/kg i.v. cHyp in liposomes every 5 days. Animals were treated for 6 months, and hydroxyproline content of blood vessels was measured.
cells. No pulmonary intravascular macrophages or tissue mononuclear phagocytes were identified in the tissue specimens. Negatively stained liposomes in vitro were morphologically similar to those found in tissue; however, the liposomes in tissue were slightly reduced in diameter because of shrinkage of the tissue during preparation for electron microscopy.
Discussion
Liposomes administered intravenously are removed from the circulation by cells of RE organs and circulating phagocytic cells. 22 Liposomes are too large to pass through the walls of capillaries of most organs and do not reach extravascular cells.4 This pattern of distribution was exploited here to deliver an antifibrotic agent to blood vessel walls. We found that intravenously injected liposomes were taken up by pulmonary artery endothelial cells. Drug action was clearly improved using liposomes compared with free cHyp: intravenous delivery of cHyp in liposomes required considerably less total dose of drug to prevent pulmonary hypertension, and drug effect was sustained for 5 days after a single injection. Drug action on the pulmonary circulation could be improved by prior blockade of RE organs. Prolonged intravenous administration of cHyp in liposomes had no apparent deleterious effect on major organs except that the tensile strength of large blood vessels was reduced.
Endothelial cells in culture internalize a variety of particles by a process that involves ingestion by phagosomes.28 Our morphological observations suggest that liposomes are taken up in vivo by a similar process. Aggregates of liposomes were identified within endosomes of endothelial cells 2 hours after intravenous injection, the time of maximal uptake of liposomes by endothelial cells in culture. The mechanism of uptake of liposomes by cells involves primarily endocytosis, and endosomes containing liposomes fuse with lysosomes where enzymatic digestion takes place, releasing the contents of the liposome.29 Liposomes enter RE organs, and the vesicles may persist for days before phagocytic cells endocytose and degrade them.2-3 A similar process involving endocytosis and degradation of liposomes by endothelial cells may explain the sustained inhibitory effect of a single injection of cHyp in liposomes on vascular collagen accumulation.
Other cells may have been involved in uptake of liposomes by the lung after intravenous injection. For example, liposomes are taken up by circulating monocytes, which subsequently migrate into the arterial walls30 and airspaces of the lung.22 Monocytes containing liposomes were not identified 2 hours after injection, although translocation of liposomes in monocytes may have occurred at a later time. Pulmonary intravascular macrophages take up liposomes,31 but it is unlikely they played a role since the rat has few if any of these cells. 32 We cannot exclude the possibility that liposomes were taken up by phagocytic cells of RE organs and cHyp was released over time to the circulation. However, our results showing that a twofold uptake of liposomes in lungs by prior RE blockade reduced the effective dose by one half suggests that the endothelial cell is the important target for liposome uptake for the effects observed here.
Procollagen triple helix formation is a specific site for pharmacological modulation of collagen production by proline analogues.33 Incorporation of cHyp into pro-a chains of collagen prohibits triple helix formation, producing a nonfunctional protein that is secreted from the cell at a delayed rate34 and is rapidly degraded. 35 The net effect is decreased accumulation of collagen in tissues. Vascular collagen biosynthesis is increased in hypertension,3637 and agents that inhibit collagen formation diminish both systemic38 and pulmonary5'7 hypertension. In the rat hypoxia model, collagen biosynthesis in the main pulmonary artery is markedly increased during the first 5 days after exposure to hypoxia.37 Free cHyp prevents collagen accumulation in pulmonary arteries in the early stage of this model,5 but the agent is less effective in established hypertension.6 cHyp blocks the collagen accumulation that contributes to wall thickening and stiffening of pulmonary arterioles, thereby preventing fixed vascular obstruction.5 When cHyp was administered in liposomes, the antihypertensive effect persisted for 5 days, but 2 days later there was an abrupt rise in pulmonary blood pressure to levels found in the hypoxic animals treated with empty liposomes. We presume that after day 5 the tissue concentration of cHyp decreased to levels too low to inhibit procollagen processing. Consequently, collagen was secreted, it accumulated in flow-resistive blood vessels, and pulmonary blood pressure rapidly increased. Intermittent injections of cHyp provided a sufficient concentration of cHyp in tissues to continually inhibit collagen accumulation.
Because proline analogues are incorporated into all proteins, they are only relatively specific for inhibiting collagen synthesis under most experimental conditions. 39 We noted that total protein content of blood vessels was decreased by administration of cHyp, suggesting inhibition of noncollagen protein synthesis. Alternatively, cHyp may have interfered with the proliferation of vascular smooth muscle cells and fibroblasts in central pulmonary arteries that occurs during the first few days after rats are exposed to hypoxia.40 cHyp added to cultured fibroblasts inhibits cell growth, presumably because secreted collagenous proteins are required for the cells to attach and grow.41 If cell-matrix interactions are important for vascular cells to proliferate in situ, cHyp may have suppressed the ability of the cells to divide during the early remodeling period, and this may explain the observed decrease in total protein in pulmonary arteries. cHyp also inhibits collagen deposition in bone marrow cultures, thereby preventing the establishment of a stroma required to support proliferation and differentiation of erythropoietic progenitor cells. 42 It is possible that cHyp inhibited newly synthesized collagen in bone marrow that was required to support the growth of erythropoietic precursor cells stimulated by hypoxia. This may account for the suppression of secondary polycythemia noted during the first few days after exposure to hypoxia.
The only observed effect of long-term administration of cHyp in liposomes was diminished tensile strength of main pulmonary arteries and aortas. Collagen content was not decreased in vessels with altered mechanical properties; however, the overall quantity of connective tissue in vessels does not correlate with stiffness.43
Interestingly, the mechanical properties of only large arteries were affected. Vessels with the greatest pulsa- .0( collagen, cHyp may have had a greater effect on distensible elastic arteries. Moreover, according to the law of Laplace, wall tension is greater in large than in small arteries,'4 predisposing to further weakening of the wall by breakdown of collagenous fibers. The long-term administration of cHyp in liposomes probably affected the tensile properties of normotensive aortas by interfering with the slow rate of collagen synthesis.36,37 These results are consistent with the notion that the pharmacological effect of cHyp in liposomes injected intravenously is confined to the vascular compartment. Hypertensive arteries undergo damage and repair, requiring a system for regulating synthesis and degradation of connective tissue. Increased synthesis is also accompanied by increased turnover, so the half-life for aortic collagen in rats with systemic hypertension is reduced from 60-70 days to 17 days. 36 Collagenolytic activity in blood vessel walls may contribute to accelerated turnover of vascular collagen.45'46 Treatment with an antifibrotic agent may alter the balance between synthesis and degradation, producing reversal of excess collagen in sclerotic blood vessels. Prolonged administration of 8-aminopropionitrile, an agent that blocks the formation of cross-links in collagen, lowers blood pressure and reduces vascular collagen in rats with established systemic hypertension.38 Dietary deficiency of ascorbic acid (scurvy) leads to impairment of peptidyl hydroxylation of procollagen,47 which is thought to be the basis of the disruption of connective tissue in the media and adventitium of blood vessel walls.48 In hypertensive blood vessels, the increased rate of collagen synthesis36 and greater uptake of liposomes30,49 suggest it may be feasible to reverse collagen accumulation in remodeled arteries by continuous treatment with cHyp in liposomes.
Recent work has shown that uptake of liposomes is increased in atherosclerotic30 and hypertensive49 aortas of rabbits and that liposome localization paralleled the distribution of monocytes and macrophages in atherosclerotic aortas. 30 One implication of these observations to our study is that uptake of cHyp in liposomes may have been increased in hypertensive pulmonary arteries and may account in part for the improved drug effect. We attempted to measure uptake of radiolabeled liposomes in main pulmonary arteries, but counts were too low to determine whether hypertension increased liposome uptake (data not shown). A second implication is that the type of vascular cell that takes up liposomes may vary depending on the disease or the vascular bed. Uptake by phagocytic cells may be important in inflammatory vascular disorders, whereas endothelial cells may predominate in noninflammatory diseases.
In conclusion, we have established that liposomes injected intravenously deliver agents to blood vessel walls that interfere with metabolic processes involved in hypertensive vascular disease. Antifibrotic agents delivered by this route may be effective for inhibiting vascular sclerosis.
